Joseph P. Lyssikatos, Chief Scientific Officer: Enliven Therapeutics ELVN Sell · Filed 25/07/23

Trade details

Type: Insider sale
Amount: $265,428.24
Shares · price: 11,924 sh · $22.26 a share
Held after: 953,264 sh
Stock: Enliven Therapeutics ELVN
Person: Joseph P. LyssikatosChief Scientific Officer
Trade date: 25/07/21
Filed: 25/07/23
Days to filing: 2 days

Sold 1.2% of holdings

Share of holding sold: 1.2%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 25/06/21~25/08/20

Joseph P. Lyssikatos's recent trades

Joseph P. LyssikatosChief Scientific Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$1.1M
25,000 sh
$1.1M
Filed 04/30
Traded 04/30
Joseph P. LyssikatosChief Scientific Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$914.8K
25,000 sh
$914.8K
Filed 03/31
Traded 03/31
Joseph P. LyssikatosChief Scientific Officer
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$2M
75,000 sh
$2M
Filed 02/18
Traded 02/18
Joseph P. LyssikatosChief Scientific Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$145.2K
5,000 sh
$145.2K
Filed 02/10
Traded 02/06
Joseph P. LyssikatosChief Scientific Officer
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$390.3K
14,509 sh
$390.3K
Filed 01/22
Traded 01/20

Joseph P. Lyssikatos, Chief Officer — sold $265.4K of Enliven Therapeutics ELVN · 1.2% of holdings · 10b5-1 plan | Whalegun